Identification of a novel set of genes reflecting different in vivo invasive patterns of human GBM cells by Massimiliano Monticone et al.
Monticone et al. BMC Cancer 2012, 12:358
http://www.biomedcentral.com/1471-2407/12/358RESEARCH ARTICLE Open AccessIdentification of a novel set of genes reflecting
different in vivo invasive patterns of human GBM
cells
Massimiliano Monticone1, Antonio Daga1, Simona Candiani2, Francesco Romeo1,3, Valentina Mirisola1,
Silvia Viaggi1,2, Ilaria Melloni1, Simona Pedemonte1, Gianluigi Zona1, Walter Giaretti1, Ulrich Pfeffer1 and
1*Patrizio CastagnolaAbstract
Background: Most patients affected by Glioblastoma multiforme (GBM, grade IV glioma) experience a recurrence of
the disease because of the spreading of tumor cells beyond surgical boundaries. Unveiling mechanisms causing
this process is a logic goal to impair the killing capacity of GBM cells by molecular targeting.
We noticed that our long-term GBM cultures, established from different patients, may display two categories/types
of growth behavior in an orthotopic xenograft model: expansion of the tumor mass and formation of tumor
branches/nodules (nodular like, NL-type) or highly diffuse single tumor cell infiltration (HD-type).
Methods: We determined by DNA microarrays the gene expression profiles of three NL-type and three HD-type
long-term GBM cultures. Subsequently, individual genes with different expression levels between the two groups
were identified using Significance Analysis of Microarrays (SAM). Real time RT-PCR, immunofluorescence and
immunoblot analyses, were performed for a selected subgroup of regulated gene products to confirm the results
obtained by the expression analysis.
Results: Here, we report the identification of a set of 34 differentially expressed genes in the two types of GBM
cultures. Twenty-three of these genes encode for proteins localized to the plasma membrane and 9 of these for
proteins are involved in the process of cell adhesion.
Conclusions: This study suggests the participation in the diffuse infiltrative/invasive process of GBM cells within the
CNS of a novel set of genes coding for membrane-associated proteins, which should be thus susceptible to an
inhibition strategy by specific targeting.
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The Glioblastoma multiforme (GBM, stage IV Glioma)
arise from neuroglial cells or their progenitors and repre-
sents the most aggressive brain tumor, with 15 months
median survival after diagnosis, causing 4% of all cancer-
related death despite recent improvement of diagnostic
and treatment procedures. Surgery represents the stand-
ard treatment procedure. However, the vast majority of
the patients affected by GBM experience a recurrence of* Correspondence: patrizio.castagnola@istge.it
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distribution, and reproduction in any mediumthe disease because of the spreading of cells beyond the
limits of the resection [1]. The identification of the
affected region of the central nervous system (CNS) to be
resected is a major challenge. Neither advanced imaging
techniques nor histological examination warrant against
leaving some tumor cells in adjacent normal-looking brain
tissue. Histologically normal brain tissue acquired at a dis-
tance greater than 4 cm from the GBM/Oligodendrogli-
oma tumor was shown to give rise to tumor colonies in
soft agar culture [2]. Therefore, the ability of GBM cells to
invade the host tissue is one of the biological features of
this disease that eventually has the most detrimental im-
pact on the life expectancy of the patient [1]. In addition,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of the CNS with an intact blood–brain barrier. As a conse-
quence, the targeting of the GBM invasion process is a
major topic of interest [3-5].
In the past years, some reports have focused on the in-
verse relationship between growth/apoptosis sensitivity
and migration of glioma cells [6] and production by gli-
oma cells of factors able to enhance invasion in an auto-
crine fashion [5]. Other research groups have shown the
ability of the microenvironment to influence migration
properties via cell-extracellular matrix interactions and
paracrine stimuli [3,4,7-9].
Key to the study of GBM invasion is the availability of a
reliable culture system, in order to preserve the tumori-
genic potential of cells derived from patients, and of
“in vivo” models suitable to address questions and test hy-
pothesis concerning this process.
To these aims, we have successfully established long-
term cell cultures from surgical tumor samples obtained
from several GBM patients and demonstrated their ability
to generate GBM xenografts by serial transplantation
[10,11]. In particular, we observed that these cultures dis-
played two types of “in vivo” growth behavior in these
transplants. The first one was mainly expansive while the
second, causing the host’s white and gray matters substitu-
tion by tumor cells, was highly diffusive. The aim of the
present study was to identify by microarray analysis if the
two GBM culture types were characterized by differential
gene expression. We actually identified a set of differen-
tially expressed genes. Some of these were known to be
involved directly or indirectly in promoting glioma inva-
sion, which supported our results [12-14]. Other genes,
however, were not previously described in association with
glioma invasion. This study provides, therefore, a novel set
of potential target genes for future research and develop-
ment of treatment strategies intended to inhibit the inva-
sion by GBM cells of healthy brain tissue.
Methods
Cell cultures
Long-term GBM cell cultures were obtained from surgical
samples of tumors provided by the Neurosurgery Depart-
ment of the San Martino Hospital in Genoa. An informed
consent was obtained from all patients before surgery as
required by the Ethic Board. Patients and tumors character-
istics are provided in Table 1.
Cells isolation was described in detail elsewhere [11,16].
Briefly, bioptic samples were plated in regular plastic dishes
using proliferation medium. One to two weeks after plat-
ing, cellular aggregates, resembling neurospheres derived
from normal neural precursors, were detectable in all glio-
blastoma cultures. Neurospheres-like aggregates were col-
lected, dissociated to obtain a single cell suspension and
seeded on Matrigel (BD Biosciences, San Jose, CA, USA)coated flasks. Under these conditions, cells grown as a
monolayer gave rise to tumor when injected orthotopically
in nude mice [11,16]. In addition, these long-term cultures
of GBM tumorigenic cells maintained the ability to gener-
ate neurospheres-like aggregates repeatedly when trans-
ferred into flasks lacking Matrigel coating. In particular, the
long-term cultures of GBM tumorigenic cells used in the
present study did not show differences in growth pattern
in vitro because they were all able to attach, spread and
proliferate on Matrigel. Similarly, when seeded in culture
flasks lacking the Matrigel coat, they were all able to gener-
ate neurosphere-like aggregates and proliferate with no
major phenotype differences in neurosphere dimension
and appearance (data not shown).
The proliferation medium was DMEM-F12/Neurobasal
additioned with 1%v/v B27 supplement, (Gibco Ltd, Paisley,
Scotland), 2 mM L-glutamine (Gibco Ltd), recombinant
human fibroblast growth factor (FGF-2, 10 ng/ml Peprotech,
London, UK), recombinant human epidermal growth factor
(EGF, 20 ng/ml Peprotech). The medium was changed twice
a week. Normal human astrocytes were purchased from
ScienCell Research Laboratories (Carlsbad, CA) and cultured
following the manufacturer’s instructions. Normalized expres-
sion levels for selected stem cell markers, nervous system
markers, PDGF receptors and IDH genes in the tumorigenic
long-term GBM cell cultures used in this study, are shown in
Additional File 1: Table S1.
Intracranial tumorigenicity assays
Human GBM cells in vivo tumorigenicity was tested by
cell intracranial inoculation in 6 – 8-week-old NOD/SCID
mice (Charles River Laboratories, Lecco, Italy).
NOD/SCID mice were housed in pathogen-free condi-
tions, according to the National Regulation on Animal
Research Resources. For intracranial inoculation, at least
three mice for each GBM cell culture were used. Mice were
anesthetized with i.m. ketamine and xylazine. Thereafter, the
animal was positioned into a stereotactic frame (David Kopf
Instruments, Tujunga, CA, USA) and a hole was made
2 mm lateral and 1 mm anterior from the bregma. Cells
(105) were injected using a Hamilton syringe (Sigma-Aldrich,
Milan, Italy) at a depth of 3.5 mm in a vol of 2 μl. Mice were
monitored for about 6 months for disease symptoms and
were sacrificed by CO2 asphyxiation when they showed
weight loss or any severe sign of disease. The brains of all
sacrificed mice were collected and processed for histology.
The survival in days of mice inoculated with the long-term
GBM cultures used in this study is reported in Table 1.
All experiments were performed in compliance with
guidelines approved by the Ethical Committee for Animal
Use in Cancer Research at the Istituto Nazionale per la
Ricerca sul Cancro in Genoa, Italy. Under our experimen-
tal conditions, the minimum number of GBM cells
required to give rise to tumor in mice was 104.






















PT1 M 67 IV new cortical right temporal-
occipital
No No 55-65c






PT3 M 53 IV second
recurrence




PT4 M 51 IV new undercortical right temporal-
parietal
No No 90-110c
PT5 F 70 IV new cortico-
undercortical
right frontal No No 90-110c





These cells generated serially transplantable tumors in vivo. Survival mice data represent range of days required to induce large brain tumors and the sacrifice of
the animals after injection of 105 GBM cells derived from explants of primary tumors (secondary tumors).
aWorld Health Organization (WHO) criteria for brain tumor classification.
bDetermined by Nuclear Magnetic resonance.
cThese data for the corresponding patient GBM long-term cell cultures were published by Griffero and collaborators [15].
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Total RNA was isolated from cultured GBM cells using
miRNeasyW mini kit (Qiagen, Milan, Italy) with DNase
treatment. RNA concentration and purity were determined
by measuring absorbance at 260 and 280 nm; 2 μg total
RNA was run on a 1% denaturing gel and 100 ng were
loaded on the 2100 Bioanalyzer (Agilent, Palo Alto, CA) to
verify RNA integrity.
Amplification of RNA and array hybridization
According to the recommendations of the manufacturer,
100 ng of total RNA was used in the first-round synthesis of
double-stranded cDNA. The RNA was reverse-transcribed
using a Whole Transcript cDNA synthesis and amplification
kit (Affymetrix UK Ltd., High Wycombe, UK). The resulting
biotin-labeled cRNA was purified using an IVT clean-up kit
(Affymetrix) and quantified using a UV spectrophotometer
(A260/280; Beckman, Palo Alto, CA). An aliquot (15 μg) of
cRNA was fragmented by heat and ion-mediated hydrolysis
at 94°C for 35 minutes. The fragmented cRNA, run on the
Bioanalyzer (Agilent Technologies, Santa Clara, CA) to
verify the correct elettropherogram, was hybridized in a
hybridization oven (16 hours, 45°C) to a Human Gene 1.0
ST array (Affymetrix) representing whole-transcript cover-
age. Each one of the 28869 genes was represented on the
array by approximately 26 probes spread across the full
length of the gene, providing a more complete and more
accurate picture of gene expression than the 3’ based ex-
pression array design. The washing and staining procedures
of the arrays with phycoerythrin-conjugated streptavidin
(Invitrogen, Monza, Italy) was completed in the FluidicsStation 450 (Affymetrix). The arrays were subsequently
scanned using a confocal laser GeneChip Scanner 3000 7 G
and the GeneChip Command Console (Affymetrix).
GeneChip microarray analysis and data normalization
Affymetrix raw data files [cell intensity (CEL) files] were
used as input files in expression console environment
(Affymetrix). Briefly, CEL files were processed using the
Robust Multi-Array Analysis (RMA) procedure [17], an al-
gorithm that is publicly available at http://www.bioconduc-
tor.org. The RMA method was used to convert the
intensities from the multiple probes of a probe set into a
single expression value with greater precision and
reduced background noise (relying on the perfect match
probes only and thus ignoring the mismatch probes) and
then to normalize by sketch quantile normalization.
Quality assessments were also performed in the expres-
sion console environment. This procedure, based on vari-
ous metrics, allowed us to identify a chip as an outlier
(see for details Quality assessment of exon and gene
arrays http://www.affymetrix.com/support/technical/white-
papers/exon_gene_arrays_qa_whitepaper.pdf). Significance
Analysis of Microarrays (SAM), Principal Component Ana-
lysis (PCA) of variance and Hierarchical Clustering (HCL),
after mean scaling and log2 transformation, were per-
formed with the software tool from The Institute for Gen-
omic Research (TIGR) MeV (multiple experimental viewer)
(http://www.tigr.org/software/tm4/mev.html) [18].
Individual genes with different expression levels, among
the two groups, were identified using SAM [19]. The false
discovery rate expressed as q-value was used to evaluate
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trary filter was applied excluding all genes that did not ex-
hibit a difference in expression of at least 2-fold. Genes
differentially expressed were investigated using a two-class
analysis.
We used PCA to reduce the complexity of high-
dimensional data and to simplify the task of identifying pat-
terns and sources of variability in these large data sets. The
results from SAM were visualized using HCL [20]. All the
microarray information has been submitted to the National
Center for Biotechnology Information Gene Expression
Omnibus web site (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?token=zfutlaeiauqmmbo&acc=GSE16805).
Pathways identification by Expression Analysis Systemic
Explore (EASE)
Gene lists from Affymetrix results were examined using the
EASE program, accessible via http://david.abcc.ncifcrf.gov/.
EASE is a customized stand-alone software application with
statistical functions for discovering biological themes within
gene lists. This software assigns genes of interest into func-
tional categories based on the Gene Ontology database
(GO, http://www.geneontology.org/index.shtml) and uses
the Fisher's exact test statistics to determine the probability
of observing the number of genes within a list of interest
versus the number of genes in each category on the array.
A more detailed analysis of the genes' association with
physiological pathways was performed using the Kyoto
Encyclopedia of Genes and Genomes (KEGG, http://www.
genome.jp/kegg/pathway.html). Each identified process
was confirmed through PubMed/Medline (http://www.
ncbi.nlm.nih.gov/sites/entrez?db=pubmed).
RT-PCR analysis
Starting from about 1 μg of total RNA, cDNA was
synthesized by using an Oligo(dT)20, random hexamers
mix and a Superscript III first-strand synthesis system
supermix for RT-PCR (Invitrogen). cDNAs, diluted 5–20
times, were then subjected to PCR analysis.
Relative quantification was performed by real-time
quantitative RT-PCR (qPCR). Briefly, qPCR was per-
formed and analyzed using the Mastercycler ep Realplex
(Eppendorf AG, Hamburg, Germany). Primers were
designed across a common exon–exon splice junction
by using the tool available at https://www.roche-applied-
science.com/sis/rtpcr/upl/index.jsp?id=UP030000 (Roche
Applied Science, Monza, Italy)(see Additional File 2:
Table S2). Reactions were carried out in triplicates and
amplicons were measured by SYBR Green fluorescence
(5 Prime, Hamburg, Germany) according to the manu-
facturer's recommendations. The dissociation curve ana-
lysis was used to define the specificity of the products by
the presence of a single dissociation peak on the thermal
melting curve.The gene coding for the peptidyl-prolyl cis-trans isomer-
ase A (PPIA) was used as the endogenous control for
normalization because, in the microarray data, it showed in
all conditions the steadiest expression in our experimental
setting when compared with other housekeeping genes.
Multiplex ligation-dependent probe amplification (MLPA)
analysis
Genomic DNA was isolated from long-term GBM cell cul-
tures and normal human astrocytes using QIAamp DNA
microkit (Qiagen). The MLPA analysis (SALSA MLPA
KITs P175-A1 Tumour-Gain and P294-A1 Tumour-loss,
(MRC Holland, Amsterdam, the Netherlands) was per-
formed using 100 ng of genomic DNA, diluted in 5 μl of
TE buffer, following the manufacturer’s instructions. The
resulting DNA fragments were identified and quantified by
using capillary electrophoresis on an ABI XL3130 genetic
analyzer (Applied Biosystems, Foster City, CA, USA) and
the Genemapper program (version 4.0 - Applied Biosys-
tems). Data were analyzed with the Coffalyser software
(MRC-Holland). For each patient long-term culture of
tumorigenic GBM cells, gains and losses were assigned by
comparing the peaks between the patient and the reference
samples (DNA from normal human astrocytes). A value =0
was considered as a biallelic loss, a value <0.7 corresponded
to a DNA loss, a value between 1.3 and 2.0 corresponded
to a DNA gain. The examined region was defined as ampli-
fied for values >2. All experiments were done in triplicate.
Fluorescence in situ hybridization (FISH)
FISH was performed using a whole chromosome painting
for chromosome 10 (WCP-10), obtained from Mariano
Rocchi, Resources for Human Molecular Cytogenetics
Project, by Telethon and the Italian Association for Cancer
Research (AIRC). WCP-10 was amplified and labeled with
Cy-dUTP (Amersham Pharmacia Biotech, Piscataway, NJ,
USA) by degenerate oligonucleotide-primed polymerase
chain reaction (DOP-PCR) [21]. Hybridization was per-
formed as described [22], with minor modification. Briefly,
slides carrying metaphase spreads were denatured in 70%
(vol/vol) formamide/2x SSC, pH 7, at 70°C for 2 min], and
dehydrated in a 4°C ethanol series. The hybridization mix
consisted of 50% formamide, 2x SSC, 10% dextran sulfate,
carrier DNA (sonicated salmon sperm DNA) at 500 μg/ml,
human DNA C0t1 and Cy3-labeled WCP-10 at 2 μg/ml.
This mixture was denaturated at 76°C for 6 min, incubated
at 37°C for 30 min, applied to the slides under a glass
coverslip, and sealed with rubber cement. After overnight
incubation at 37°C in Hybrite™ (Abbott Molecular/Vysis,
Abbott Park, IL, USA), the slides were washed for 2 min at
72°C in 0.4x SSC/0.3% NP40, pH 7 and for 1 min at R.T. in
2x SSC/0,1% NP40, pH7. Slides were counterstained with
4’,6- Diamidino-2-phenylindole, DAPI (Sigma-Aldrich) and
mounted in Mowiol. Hybridization signals were evaluated
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cence (Provis AX70, Olympus, Milan, Italy), and images
were acquired with a digital CCD camera C4742 Orca II
(Hamamatsu, Japan) driven by Cytovision (Applied Imaging
Corp., Santa Clara, CA, USA). The DAPI and Cy3 images
were acquired with selective single-bandpass filters at
1000× optical magnifications.
Immunofluorescence analysis
Antibodies for Sema5A (ab51957) were purchased from
Abcam (Abcam, Cambridge, UK). The Nestin antibody
(MAB353) was from Chemicon-Millipore (Millipore SPA,
Milan, Italy). The BCAN antibody (HPA007865) was from
Sigma-Aldrich. The Pmp2 antibody (12717-AP) was
purchased from Protein Tech (Protein Tech Group, Inc.,
Chicago, IL, USA).
For xenograft tumor analysis, brains were cryopre-
served and 10-μm cryostat (Leica Microsystems, Milan,
Italy) sections were cut. Sections bearing tumors were
identified by H&E. Cryosections containing tumors were
permeabilized in PBS containing 0.2% Triton X-100 and
blocked in 5% normal FCS-PBS. After incubation with
primary antibodies (anti-Nestin), sections were stained
with the appropriate secondary antibodies.
Cells plated on Matrigel-coated glass coverslips were
fixed in 3% paraformaldehyde in PBS, pH 7.6 containing
2% sucrose for 5 min at room temperature. After PBS
rinse, cells were permeabilized by a solution containing 20
mM Hepes pH 7.4, 300 mM sucrose, 50 mM NaCl, 3 mM
MgCl2 and 0.5% Triton X-100 for 5 min on ice. Non-
specific binding was prevented by incubation with pure
goat serum for 30 min on ice. Slides were incubated with
primary antibody in PBS supplemented with 10% goat
serum or fetal bovine serum (antibody dilution buffer) for
2 hours on ice. After extensive PBS washes, slides were
incubated for 30 min with the appropriate Alexa594 or
Alexa488-conjugated secondary antibody in antibody dilu-
tion buffer. Nuclei were stained with Hoechst 33258
(Invitrogen).
Image acquisition were performed at 23°C with an Axio-
vert 200 M microscope equipped with the following filter
sets: Zeiss 49, Zeiss 10 and Omega XF102-2 (Omega Op-
tical, Brattleboro, VT, USA), which were used to detect
Hoechst, Alexa 488 and Alexa 594 respectively.
SDS PAGE and immunoblot analysis
Cell lysates were obtained as described previously [21].
SDS PAGE and immunoblotting were performed using
precasted 4-12% polyacrylamide gels (Invitrogen) using
manufacturer’s instructions. The blotting membranes were
from Millipore (Millipore S.p.A., Vimodrone, Italy). The
Pmp2 antibody (12717-AP) was purchased from Protein
Tech (Protein Tech Group, Inc., Chicago, IL, USA). The
antibodies for Bcan, Megf10, Pcdh10, Pcdh15 and Actinwere all from Sigma-Aldrich (HPA007865, HPA026876,
HPA011220, AV50153 and A 2066, respectively). The anti-
body for CD109 (Sc-271085) was purchased from Santa
Cruz Biotechnology (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). The Gria2 antibody was acquired from
Abcam ab40878.Results
Human GBM cells in mouse orthotopic transplantation
show two distinct patterns of tumor growth and tissue
invasion
In an effort to identify genes associated with the invasive
properties of human GBM cells, we surveyed a collection
of histologic samples of mouse brains obtained after ortho-
topic transplantation of GBM cell from long-term cultures,
previously isolated from different patients (see Materials
and Methods for details). This survey led us to identify two
main patterns of behavior displayed by the tumors gener-
ated by these cultures in the host brain: nodular-like (NL-
type), mostly expansive, mainly located in the subcortical
regions of the injected hemisphere, and highly diffusive
(HD-type) with a striking infiltrative phenotype. The HD-
type GBM long-term cultures, in particular, used myelin-
ated fibers to cross the midline and invade the hemisphere
contralateral to the injection site and, with time, they finally
substituted the host’s white and gray matter, including the
cerebral cortex. For each transplanted brain, we stained
contiguous sections with hematoxylin/eosin and an anti-
human nestin antibody. This antibody allowed prompt
identification of human GBM tumorigenic cells within
mouse brains. Figure 1 shows representative images of
contiguous mouse brain sections hosting the two types
of tumors generated by the GBM cultures. In the NL-
type, the human GBM nestin-positive cells appeared to
cluster together forming mainly nodules in sections,
whereas in the HD-type, the human GBM nestin-positive
cells scattered in the host brain mostly as single cells at
both early and late stages of development (Figure 1).Cultures of human tumorigenic GBM cells display unique
chromosomal copy number aberrations unrelated to
distinct in vivo invasion patterns
To investigate whether the two different in vivo invasion
patterns of tumorigenic GBM cells used in the present study
could be related to differences in gains or losses at genomic
loci corresponding to known proto-oncogenes or tumor
suppressor genes, we performed a Multiplex ligation-
dependent probe amplification (MLPA) analysis. We investi-
gated a total of 51 loci and found a number of alterations
with respect to genomic DNA from primary cultures of
human astrocytes, used a normal control reference. We
observed that the cell cultures from each patient displayed a
unique profile of losses and gains with the only exception
Figure 1 Invasive behavior of human GBM cells in mouse
orthotopic transplantation. Hematoxylin and Eosin (HE) staining
(A, C, E) and immunofluorescence analyses (B, D, F) of mouse brains
injected with human cultured GBM cells. The immunofluorescence
analyses were performed with an anti-human nestin antibody.
Human nestin, yielding a green signal, identify GBM cells within the
host tissue. Nodular-like growth pattern at 8 weeks post-injection,
NL-type 8w (A, B; PT2). Highly diffuse and invasive growth pattern at
8 and 14 weeks post-injection, HD-type 8w (C, D; PT6) and HD-type
14w (E, F; PT6). The asterisks indicate the striatum in (C, D). Higher
magnification images of the areas whose corners are indicated by
four (L) in (C, D) are shown in (C’, D’). Arrowheads indicate tumor
nodules in (A, B). Notice in (C, D) scattered human nestin-positive
GBM cells and lack of nodules. Notice in (E, F) the complete
substitution of the host’s tissue by the engrafted human
nestin-positive GBM cells. Arrows in (E, F) indicate brain midline.
Scale bar = 500 μm in (A-F). Scale Bar = 200 μm in (C’, D’).
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cultures (see Additional File 3: Table S3). However, we also
observed that PT1, PT2 and PT3 (NL-type) cells shared a
combined DNA gain at the EGFR locus and a DNA loss at
the PTEN locus, which was not observed in the HD-type of
GBM cells (see Additional File 3: Table S3). In fact, among
HD-type of GBM cells we found either six copies of the
EGFR locus or biallelic loss at the PTEN locus or no
change at these two loci (PT4, PT6 and PT5, respectively,
Additional File 3: Table S3). To investigate whether thetwo types of tumorigenic GBM cell cultures differed for
chromosome 10 copy number, we performed a Fluores-
cence in situ hybridization (FISH) analysis using a whole
chromosome 10-specific painting probe. The result of this
analysis showed that chromosome 10 copy number cannot
differentiate the two types of tumorigenic GBM cell cul-
tures (Additional File 4: Table S4).
Cultures of human tumorigenic GBM cells displaying
distinct in vivo invasion patterns display a set of
differentially expressed genes
We hypothesized that the different in vivo invasion pattern
observed could be related to gene differentially expressed in
the two groups of long-term tumorigenic GBM cultures. In
order to identify these genes, we compared the gene ex-
pression patterns, obtained by microarray analysis per-
formed on the Affymetrix platform. In particular, we used
the TIGR MEV program and mRNAs extracted from GBM
cultures previously isolated from patients 1–3 (PT1-3),
belonging to the NL-type and from GBM cultures previ-
ously isolated from patients 4–6 (PT 4–6) belonging to the
HD-type.
The principal component analysis (PCA), performed
with the gene expression data, showed that samples
belonging to the HD-type clustered together and could be
promptly sorted from those belonging to the NL-type, pos-
sibly reflecting that HD-type samples were more homoge-
neous with respect to NL-types (Figure 2). Each dot in the
two-dimensional plot represented one sample. The dis-
tance between any pair of dots was related to the similarity
between the two observations in high-dimensional space.
Samples that were near each other in the plot were similar
in a large number of variables, i.e., expression level of indi-
vidual genes.
It should be noticed that the principal component ana-
lysis showed a scattering of the samples belonging to the
NL-type (PT1-3). Based on gene expression, a molecular
classification of glioblastoma into four different profiles
called ProNeural, Neural, Classical and Mesenchymal was
recently proposed [23]. For each of the 4 profiles, the cor-
responding centroid on the basis of the expression of 840
genes was identified. We extracted the expression profiles
of these 840 genes from our dataset to classify our samples
according to the correlation with each centroid. In this
way we classified PT1, PT2 and PT3 as Neural, PT4 and
PT6 as Mesenchymal (data not shown). Unfortunately, we
were unable to similarly classify the profile of PT5. It is
likely that PT5 was not similar to those previously pub-
lished. Therefore, because PT1-3 were all Neural, their
scattering in the principal component analysis appeared to
result from the expression of genes different from those
840 used for the classification.
A complete list of 34 differentially expressed genes by a
factor≥ 2 in the comparison between the NL-type GBM
Figure 2 Microarray analysis performed with TIGR MeV program: principal component analysis. Microarray analysis of cultured human
GBM cells generating tumor xenografts with nodular-like growth pattern, NL-type (PT1-3) or highly diffuse and invasive growth pattern, HD-type
(PT4-6). Probe sets associated to dysregulation of gene expression levels among the six samples were identified using SAM (see Materials and
Methods). Principal component analysis (PCA) is shown to provide the 2D projections onto the plane spanned by the two principal components
for the data sets for each patient.
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(Table 2). A short description of the known functions of
these genes and their full names, as reported by http://
www.genecards.org) [24], is shown in the Additional File
5: Table S5.
Differential expression of the genes included in Table 2
was visualized by a heat map obtained by hierarchical
clustering (HCL), which generates a tree (dendrogram)
to group similar objects together (Figure 3).
To gain a more mechanistic understanding of the pro-
cesses associated to the HD phenotype, the EASE score
[25] was used to identify Gene Ontology (GO) functional
categories, which were significantly over-represented. After
filtering the results, to avoid redundant and/or generic cat-
egories, two statistically significant GO term Biological
Process and Cell Compartment were found associated with
the HD-type of invasive phenotype: cell adhesion and in-
trinsic to membrane having a P-value of 1.1×10-4 and
1.9×10-5 respectively. In particular, 23 out of 34 genes were
coding for intrinsic membrane protein and among these
23 genes, 9 were associated to cell adhesion processes
(Table 2).
Validation at the protein level of the differential gene
expression by NL-type and HD-type of human GBM
tumorigenic cultures
To validate gene expression changes, we performed Real
time PCR analysis of arbitrarily selected genes (BCAN,GRIA2, MEG10, PCDH10, PCDH15, PMP2, SEMA5A and
CD109) resulting as deregulated from the gene array
experiments (Figure 4). In particular, BCAN, GRIA2,
MEG10, PCDH10, PCDH15, PMP2 and SEMA5A tran-
scripts were found at least twice more abundant in the
HD-type GBM cell cultures with respect to the NL-type
whereas the CD109 transcript was found down-regulated
in HD-type with respect to NL-type GBM cell cultures as
expected (Figure 4).
In order to investigate whether the proteins encoded by
the genes differentially expressed between HD- and NL-
type GBM cells from the gene array experiments were
actually expressed by these cells, we performed an immu-
noblot analysis focusing on those proteins encoded by the
genes whose transcript levels in the two culture types were
assayed by real time PCR analysis. We used commercially
available antibodies for Bcan, Gria2, Megf10, Pcdh10,
Pcdh15 and Pmp2 and CD109. We carried the immuno-
blot analysis on all the six GBM cell cultures used in the
study revealing the expression of these proteins. Figure 5
shows results obtained from a representative sample for
each type of GBM cells, PT2 (NL-type) and PT6 (HD-
type). Overall, we observed an agreement between the
detected protein signal intensity and the level of transcript
expression. Concerning the protein Sema5a, we performed
an immunofluorescence analysis to evaluate the differen-
tial expression in the NL- and HD-type of GBM cells be-
cause the correspondent antibody was not suitable for
Table 2 Probe sets ID, with relative mRNA Accession or Ensembl Transcript ID, gene symbols of genes regulated in the
comparison between cultures of human GBM tumorigenic cells with the highly diffusive (HD-type) and the nodular-
like (NL-type) invasive patterns, as determined by using SAM software with two-class unpaired analysis and the
additional requirement of at least a 2-fold change in gene expression (Ratio)
Probe Set ID mRNA Accession / ENSEMBL transcript ID Gene Symbol Ratio HD / NL expression q-value (%)*
1 8098021 NM_001083619 GRIA2 12.92 4.76
2 8144917 NM_000237 LPL 12.41 7.14
3 8151525 NM_002677 PMP2 10.90 4.76
4 7933672 NM_033056 PCDH15 10.68 4.17
5 7906205 NM_021948 BCAN 10.39 4.17
6 8168517 NM_005296 LPAR4 8.11 6.25
7 8097449 NM_032961 PCDH10 7.97 27.32
8 8107722 NM_032446 MEGF10 6.53 13.83
9 8135705 NM_012281 KCND2 6.36 22.98
10 8103736 NM_007281 SCRG1 6.14 0.00
11 8110932 NM_003966 SEMA5A 5.59 19.23
12 8065071 NM_198391 FLRT3 5.55 0.00
13 8146403 NM_018967 SNTG1 5.48 29.51
14 7954899 NM_001843 CNTN1 5.37 25.00
15 8055496 NM_018557 LRP1B 4.99 4.76
16 8095303 NM_015236 LPHN3 4.90 31.71
17 7947553 NM_020929 LRRC4C 4.83 5.56
18 8150978 NM_004056 CA8 4.60 0.00
19 8056457 NM_006920 SCN1A 4.51 3.70
20 8112881 ENST00000388321 — 4.48 29.51
21 8170307 NM_032539 SLITRK2 4.19 4.76
22 8162940 NM_005502 ABCA1 4.02 19.39
23 8082846 NM_004441 EPHB1 3.90 10.98
24 8037363 NM_145296 CADM4 3.88 25.17
25 7980580 NM_000153 GALC 3.57 25.00
26 7908812 NM_004767 GPR37L1 3.43 13.04
27 7970831 NM_007106 UBL3 3.22 10.98
28 8024712 NM_033064 ATCAY 2.98 4.17
29 8004081 NM_153018 ZFP3 2.96 4.76
30 8124280 NM_015864 C6orf32 0.36 3.57
31 7962579 BC095477 AMIGO2 0.29 3.45
32 8176375 NM_001008 RPS4Y1 0.21 20.80
33 8120719 NM_133493 CD109 0.18 20.72
34 8176719 NM_004681 EIF1AY 0.08 0.00
The false discovery rates are expressed as q-values1. Genes with GO term “cell adhesion”# are shown in bold whereas genes with GO term “intrinsic to
membrane”} are shown with a gray background. A short description of the known functions of these genes and their full names as reported by http://www.
genecards.org, are shown in the Additional File 5.
*The “q-value” is for each gene, the lowest False Discovery Rate at which that gene is called significant. It is like the well-known p-value, but adapted to multiple-
testing situations.
#Gene Ontology cell adhesion definition: the attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell
adhesion molecules.
}Gene Ontology intrinsic to membrane definition: located in a membrane such that some covalently attached portion of the gene product, for example part of a
peptide sequence or some other covalently attached group such as a GPI anchor, spans or is embedded in one or both leaflets of the membrane.
}Likely overbalanced gene expression as chromosome Y-linked gene (see Table 1).
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http://www.biomedcentral.com/1471-2407/12/358immunoblot analysis. The immunofluorescenceanalysis re-
sult showed higher signal intensity for Sema5a in cells
belonging to the HD-type with respect to cells belongingto the NL-type, which was similar to the signal obtained
with a non-relevant control antibody (data not shown).
Figure 6 shows a representative experiment obtained with
Figure 3 Microarray analysis performed with the TIGR MeV program: hierarchical clustering. Microarray analysis of cultured GBM cells and
generating tumor xenografts with nodular-like growth pattern, NL-type (PT1-3) or highly diffuse and invasive growth pattern, HD-type (PT4-6).
Heat map visualization obtained by hierarchical clustering (HCL). Probes corresponding to genes with similar regulation trend were placed close
to each other as well as patient’s samples with overall similar gene expression pattern. The color-ratio bar at the bottom indicates intensity of
gene up-regulation (red), down-regulation (green) and no change (black). Affymetrix Probes identification 7 digit numbers (Probe Id) along with
Gene Symbols are shown on the right. Gene name symbols used are those approved by the Human Genome Organization Gene Nomenclature
Committee (http://www.genenames.org/).
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http://www.biomedcentral.com/1471-2407/12/358GBM cells from PT2 and PT6, NL- and HD-type, respect-
ively, stained with the Sema5a antibody.Discussion
Targeting the GBM cell ability to invade the surrounding
healthy CNS tissue is a goal to be obtained at the earliest
stage of the disease in order to reduce the occurrence of
relapses after surgery.
In order to contribute to the identification of novel
target genes having a potential role in this process, we
undertook a screening study by gene expression analysis.
We first observed that cells from our collection of GBM
cultures, when transplanted in mice brains, were able to
grow either as a nodule-like mass with a tendency to re-
main confined in the subcortical regions or to pervasively
infiltrate as single cells the entire host’s CNS and eventually
substitute the host’s tissue with the GBM tissue.With this observation in mind, we hypothesized that spe-
cific genes able to drive or to inhibit the diffuse infiltrative
behavior could be found up- or down-regulated respectively
in GBM cultures displaying this in vivo phenotype.
Our gene expression analysis, by using principal compo-
nent, first demonstrated that GBM cultures belonging to
the diffuse infiltrating type clustered together separately
from those belonging to the less infiltrating class. Secondly,
cell adhesion appeared predominant among the functional
processes associated to the 34 differentially expressed
genes. Moreover, most genes belonging to this regulated
set (23) appeared to encode for proteins intrinsic to the
plasma membrane.
Real time PCR, immunofluorescence and immunoblot
analyses, performed by using probes against eight arbitrar-
ily selected gene products out of thirty-four, confirmed the
differential regulation determined by microarray gene ex-
pression analysis.
Figure 4 Real-Time RT-PCR validation of microarray data. Real-Time RT-PCR analysis performed on cultured GBM cells generating tumor
xenografts with nodular-like growth pattern, NL-type (PT1-3) or highly diffuse and invasive growth pattern, HD-type (PT4-6) to validate the
microarray data. This was accomplished on randomly selected genes from Table 2 and showed, in arbitrary units. Expression levels are relative to
the expression of the housekeeping peptidyl-prolyl cis-trans isomerase A (PPIA) gene transcript. Standard deviations are indicated as vertical bars.
Gene name symbols used are those approved by the Human Genome Organization Gene Nomenclature Committee
(http://www.genenames.org/).
Monticone et al. BMC Cancer 2012, 12:358 Page 10 of 13
http://www.biomedcentral.com/1471-2407/12/358
Figure 5 Validation of gene expression regulation by
Immunoblot analysis. Western blot analyses were performed with
lysates of cultured human GBM tumorigenic cells PT2 (belonging to
the NL-type; NL) and PT6 (belonging to the HD-type; HD)
challenged with Bcan, Gria2, Megf10, Pcdh10, Pcdh15, Pmp2 and
CD109 antibodies. Each membrane was subjected to antibody
stripping and rechallenged with an anti-actin antibody used as
loading control.
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http://www.biomedcentral.com/1471-2407/12/358Interestingly, among the genes that we found to be
up-regulated in the HD-type, a few like GRIA2, BCAN
and LPAR4 were already shown to be directly or indir-
ectly implicated with glioma cell invasion [12-14,26].
It is worth of note that because we did not observe a dif-
ferential regulation of genes downstream of the EGFR,
PI3K, P53 and AKT pathways, the combination of gains at
the EGFR locus and losses at the PTEN locus, found in
the NL-type and not present in the HD-type of cultures,
was likely not responsible for the different in vivo invasion
behavior. One of the possible explanations, for this lack of
differential regulation of genes downstream of the men-
tioned pathways, is the finding of amplification at the
EGFR locus (six copies) in PT4 and the biallelic loss at the
PTEN locus in PT6 (both HD-type cells), which may re-
sult in stimulation of these pathways similar to the com-
bination of monoallelic EGFR gain and PTEN loss.
Our data also showed that, although the long-term
tumorigenic GBM cultures used in this study displayed loss
of heterozygosis (LOH) at specific loci on chromosome 10q
(i.e., PTEN and RET), they contained 2 copies (PT2, PT3,
PT5, PT6) or 3 copies (PT1, PT4) of chromosome 10, inde-
pendently from the in vivo invasion behavior. Therefore,
monosomy for chromosome 10, which is frequent but not
always observed in GBMs [27], could not be responsible for
the observed different invasive property of these cells.
The difference in invasive behavior among HD-type and
NL-typecould reflect in part the fact that two of the HD-
type cultures were Mesenchymal (PT4 and PT6) whereas
the NL-types were all Neural according to a GBM signature
previously reported [23]. Interestingly, Tchoghandjian and
collaborators, observed similar infiltrative and multifocal
clusters in vivo invasion patterns displayed by Mesenchy-
mal and Neural GBM-derived stem-like cells, respectively
[28]. The result that BCAN was found expressed at the
highest level in PT5 and PT6, which we classified as Mes-
enchymal, is in apparent disagreement with previous stud-
ies [23,29]. However, several reports showed that BCAN is
associated to invasive glioma and promotes glioma invasion
after proteolytic cleavage and fibronectin binding
[12,14,30–34], which support our data. Moreover, the sig-
nature published by Verhaak and collaborators [23], which
included BCAN and classified GBM cells, was based on the
global expression of 840 genes. Therefore, in our opinion,
Figure 6 Validation of gene expression regulation by Immunofluorescence analysis. Indirect immunofluorescence analysis was performed
on cultured human GBM tumorigenic cells PT2 (belonging to the NL-type) and PT6 (belonging to the HD-type), by using a specific antibody
anti-Sema5A (green signal). Nuclei were stained by the Hoechst dye (blue signal). Merged imaged are shown. Scale bar = 20 μm.
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http://www.biomedcentral.com/1471-2407/12/358some variation in the expression of a single gene may still
occur without affecting GBM cell classification.
Previous studies have linked GBM cell lines in vitro and
in vivo transplant growth patterns as well as gene signa-
tures with cortical and deep tumor location in patient
brains [28,29,35,36]. The analysis of the patient tumor
characteristics, from which the long-term GBM cultures
were established in our study, showed overall similarity in
tumor location and lobe oforigin between the two invasive
behavior types. A possible exception might be the frontal
lobe involvement, which was present in two out of three
patientsfrom which were derived the HD-type GBM cells
and absent from those patients from which were estab-
lished the NL-type of GBM cells. In our opinion, our series
of cases is small to confirm or disprove a significant correl-
ation between in vitro and in vivo growth patterns and in-
vasive phenotype and tumor or patient characteristics,
which was, however, not the aim of this study.
Conclusions
In conclusion, we think that the present study has identi-
fied for the first time a set of genes that are likely to be
implicated in the diffuse infiltration ability of GBM cells. In
addition, most of the genes in this set encode for mem-
brane proteins, which are, therefore, amenable to in vivo
targeting approaches with conventional or recombinant
antibodies.
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